Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EMA Starts Review of Aripiprazole 2-Month Injectable: Otsuka/Lundbeck
June 20, 2022
- Kissei-Originated Fibroid Drug Approved in Europe
June 20, 2022
- Samsca Authorized Generic Hits Shelves in Japan
June 20, 2022
- Taisho’s Lusefi OD Film Now Available in Japan
June 20, 2022
- Takeda Founding Family to Vote against Foreign Leadership
June 17, 2022
- Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
- Nihon Medi-Physics Launches AMED-Funded Project to Develop Antibody-RI Conjugates
June 16, 2022
- Ajovy Auto-Injector Approved in Japan: Otsuka
June 16, 2022
- Shionogi to Expand Access for Cefiderocol in Low- and Middle-Income Nations
June 16, 2022
- Asahi Kasei Snags Rights to Tsukuba Upstart’s CKD Drug Candidate
June 15, 2022
- Daiichi Sankyo Kicks Off PIII to Test ADC Follow-Up for Triple-Negative Breast Cancer
June 15, 2022
- Sanofi Set for Dupixent’s Pediatric Eczema Filing in Japan after Positive Data
June 15, 2022
- Otsuka Ties Up with xFOREST on RNA Structure-Targeted Drug Discovery
June 14, 2022
- Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- FDA Accepts Resubmission for Santen/Ube’s Glaucoma Med
June 13, 2022
- Kasper Bødker Mejlvang Tapped as New Novo Japan Chief
June 13, 2022
- AstraZeneca Japan Chief Stefan Woxström Standing Down, Successor Yet to Be Named
June 13, 2022
- Takeda’s Dengue Vaccine Proves 4.5-Year Protection
June 10, 2022
- Chugai Challenges Ruling in Method-of-Use Patent Case for Edirol
June 10, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…